Truist Securities Maintains Hold on Evolent Health, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Neutral 55.1%

Neg 0% Neu 55.1% Pos 0%

Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Hold and lowers the price target from $7 to $6.